# Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

> **NCT00925600** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 769 (actual)

## Conditions studied

- Cancer
- Cataract
- Low Bone Mineral Density
- Osteopenia
- Osteoporosis
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Denosumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00925600
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-30
- **Primary completion:** 2016-05-12
- **Final completion:** 2016-05-12
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925600, "Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00925600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*